^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TCR modulator

    Related drugs:
    1d
    Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, University Health Network, Toronto | Trial completion date: Sep 2025 --> Nov 2026 | Trial primary completion date: Sep 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CTAG1B (Cancer/testis antigen 1B)
    |
    cyclophosphamide • fludarabine IV • mipetresgene autoleucel (TBI-1301)
    3d
    T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers (clinicaltrials.gov)
    P1, N=36, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Site plans to become a site for a multicenter study of this therapy
    Trial termination • IO biomarker
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Zuplenz (ondansetron oral dispersible film)
    16d
    An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, China Immunotech (Beijing) Biotechnology Co., Ltd.
    New P1 trial
    16d
    Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, China Immunotech (Beijing) Biotechnology Co., Ltd.
    New P1 trial
    17d
    EVOLVE platform, a trispecific T cell engager with integrated CD2 costimulation, for the treatment of solid and hematologic tumors. (PubMed, Proc Natl Acad Sci U S A)
    The CD2 receptor is an attractive costimulation target owing to its association with T cell receptor signaling and favorable expression profile...We demonstrate that ULBP2-targeted trispecifics with integrated CD2 costimulation and optimized CD3 affinity are superior to higher-affinity CD3 molecules in in vivo mouse efficacy studies. This integrated CD2 costimulation platform, which we termed EVOLVE, represents a next-generation TCE platform to increase T cell effector function in the tumor microenvironment and has the potential to address unmet patient needs by improving the depth and durability of clinical antitumor T cell responses.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD20 (Membrane Spanning 4-Domains A1) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • CD58 (CD58 Molecule) • CD2 (CD2 Molecule) • ULBP2 (UL16 Binding Protein 2)
    |
    T-cell receptor therapy
    18d
    TSCAN-002: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=840, Active, not recruiting, TScan Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Pan tumor
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702
    30d
    TITAN: A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies. (clinicaltrials.gov)
    P1, N=54, Recruiting, AstraZeneca | Trial primary completion date: Feb 2027 --> Jun 2027
    Trial primary completion date
    2ms
    Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, The First Hospital of Jilin University
    New P1 trial
    |
    tirbanibulin oral (KX-01 oral)
    2ms
    Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations. (PubMed, Trends Cancer)
    Human leukocyte antigen (HLA)-based immunotherapeutics, such as tebentafusp-tebn and afamitresgene autoleucel, have expanded the treatment options for HLA-A*02-positive patients with rare solid tumors such as uveal melanoma, synovial sarcoma, and myxoid liposarcoma...Last, we emphasize the urgent need for further research to better understand HLA allotype heterogeneity and its influence on tumor immunopeptidome-driven immune responses. We anticipate that these strategies will accelerate the development and implementation of both personalized and broad-spectrum HLA-based immunotherapies, and will ultimately improve cancer treatment across genetically heterogeneous patient populations worldwide.
    Review • Journal
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02 positive
    |
    Kimmtrak (tebentafusp-tebn) • Tecelra (afamitresgene autoleucel)
    2ms
    Identification and non-clinical characterization of SAR444200, a novel anti-GPC3 NANOBODY® T-cell engager, for the treatment of GPC3+ solid tumors. (PubMed, Mol Cancer Ther)
    The highly potent and efficacious activity of SAR444200 in diverse models of GPC3+ tumors and the extremely wide tolerated dose range merits further development of this compound. Furthermore, NANOBODY®-based TCEs developed using an anti-TCRαβ moiety may have specific advantages for the development of TCEs.
    Journal • IO biomarker
    |
    GPC3 (Glypican 3) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex)
    |
    SAR444200
    2ms
    Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, TCRx Therapeutics Co.Ltd
    New P1 trial
    |
    tirbanibulin oral (KX-01 oral)